Month: January 2024

Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders

Back

Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders

Read More

Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment

Back

Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment

Read More